Circassia Pharmaceuticals PLC  

(Public, LON:CIR)   Watch this stock  
Find more results for Charles L. Cummings
+0.40 (0.16%)
Real-time:   3:28PM GMT
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 252.45 - 255.40
52 week 247.00 - 320.00
Open 255.00
Vol / Avg. 31,612.00/300,282.00
Mkt cap 483.78M*
P/E     -
Div/yield     -
EPS -0.18*
Shares 189.42M
Beta     -
Inst. own     -

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -25.79% -42.95%
Return on average equity -27.09% -50.00%
Employees 20 -
CDP Score - -


The Magdalen Centre Robert Robinson Avenue The Oxford Science Park
United Kingdom - Map
+44-1865-405560 (Phone)
+44-1865-784576 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance


Circassia Pharmaceuticals plc is a United Kingdom-based specialty biopharmaceutical company. The Company is focused on the development and commercialization of a range of immunotherapy products for the treatment of allergies such as cat, grass, house dust mite and ragweed. The Company�s product portfolio is designed to treat a broad range of seasonal and perennial allergies. The Company�s product portfolio includes Cat-SPIRE, House Dust Mite-SPIRE, Grass-SPIRE, Ragweed-SPIRE, Birch-SPIRE, Japanese Cedar-SPIRE and Alternaria-SPIRE.

Officers and directors

Francesco Granata M.D. Chairman of the Board
Steven Harris Chief Executive Officer, Co-Founder
Charles Swingland Non-Executive Deputy Chairman of the Board, Co-Founder, General Counsel
Julien Cotta Chief Financial Officer, Director
Age: 50
Ian Crosbie Senior Vice President - Corporate Development
Rod Hafner Senior Vice President - Research and Development
Lara Flynn Vice President - Corporate Affairs
Stewart Sharpe Vice President - Commercial Operations
Steve Pawsey Chief Medical Officer
Russell Cummings Non-Executive Director